Limited Use Note(s)

Government of Ontario Logo
Reason For Use CodeClinical Criteria
For the treatment of osteoporosis in postmenopausal women who have:
373Failed or, experienced intractable side effects, or have a contraindication to, alendronate OR risedronate.
Failure is defined as: continued loss of bone mineral density (loss of more than 3%) after two years of therapy; or a new osteoporosis related fracture after one year of therapy.
LU Authorization Period: Indefinite.